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Abstract 23 
High-grade non-muscle invasive bladder cancer (HG-NMIBC) is a clinically unpredictable 24 
disease with greater risks of recurrence and progression relative to their low-intermediate-25 
grade counterparts. The molecular events, including those affecting the epigenome, that 26 
characterise this disease entity in the context of tumour development, recurrence and 27 
progression, are incompletely understood. We therefore interrogated genome-wide DNA 28 
methylation using HumanMethylation450 BeadChip-arrays in 21 primary HG-NMIBC 29 
tumours relative to normal bladder controls. Using strict inclusion-exclusion criteria we 30 
identified 1,057 hypermethylated CpGs within gene promoter-associated CpG islands, 31 
representing 256 genes. Bisulphite Pyrosequencing validated the array data and examined 32 
25 array-identified candidate genes in an independent cohort of 30 HG-NMIBC and 18 low-33 
intermediate-grade NMIBC. These analyses revealed significantly higher methylation 34 
frequencies in high-grade tumours relative to low-intermediate-grade tumours for the 35 
ATP5G2, IRX1 and VAX2 genes (p<0.05), and similarly significant increases in mean levels 36 
of methylation in high-grade tumours for the ATP5G2, VAX2, INSRR, PRDM14, VSX1, 37 
TFAP2b, PRRX1, and HIST1H4F genes (p<0.05). Although inappropriate promoter 38 
methylation was not invariantly associated with reduced transcript expression, a significant 39 
association was apparent for the ARHGEF4, PON3, STAT5a, and VAX2 gene transcripts 40 
(p<0.05). Herein, we present the first genome-wide DNA methylation analysis in a unique 41 
HG-NMIBC cohort, showing extensive and discrete methylation changes relative to normal 42 
bladder and low-intermediate-grade tumours. The genes we identified hold significant 43 
potential as targets for novel therapeutic intervention either alone, or in combination, with 44 
more conventional therapeutic options in the treatment of this clinically unpredictable 45 
disease. 46 
Key words: High-grade Non-Muscle Invasive Bladder Cancer, Epigenetics, Methylation, 47 
HumanMethylation450 BeadChip Array, Gene Expression 48 
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Introduction 49 
Bladder cancer is the ninth most common cancer worldwide.1 The majority of bladder 50 
cancers are transitional cell carcinomas (TCC), of which 70-80% are non-muscle invasive 51 
(NMIBC) at presentation.2 Poorly differentiated ‘high-grade’ (HG)-NMIBC is a clinically 52 
important sub-type, accounting for approximately 10-15% of all NMIBCs at presentation.3, 4, 53 
These high-grade tumours are typically more aggressive than their low- and intermediate-54 
grade counterparts, manifest by higher rates of recurrence and progression to invasive and 55 
metastatic disease despite intensive and prolonged intravesical treatment.5, 6  56 
 57 
The majority of NMIBCs are thought to be consequent to, and represent initiation and 58 
progression from, a complex interplay between sporadic, environmental, and heritable risk 59 
factors, including those that impact upon genetic and epigenetic pathways. NMIBCs and 60 
muscle invasive bladder cancers (MIBCs) have been shown to develop independently (‘the 61 
two pathway model’) on the basis of gain of function fibroblast growth factor receptor 3 62 
(FGFR3) mutations in NMIBC, and loss of function mutations in retinoblastoma 1 (RB1) and 63 
tumour protein 53 (p53) in MIBC,7-10 and have been shown to evolve from different cell 64 
types. 11, 12 However, the molecular pathways responsible for the evolution, outgrowth and 65 
progression of HG-NMIBC have not been subject to comprehensive study or investigation; 66 
indeed, it is currently unclear whether HG-NMIBCs arise as a discrete disease entity, 67 
whether they represent step-wise progression from low-intermediate-grade NMIBC tumours, 68 
or whether they sit at a molecular crossroads between NMIBC and MIBC.7, 13 11 This 69 
uncertainty is illustrated by the findings that high-grade tumours harbour abnormalities in 70 
common with low-intermediate-grade NMIBC, such as mutations of FGFR3 and/or rat 71 
sarcoma viral oncogene homolog (RAS) pathway genes14, 15, but also display extensive 72 
genetic instability and compromised regulation of vital cellular processes more in keeping 73 
with MIBC.14, 16 74 
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Epigenetic modifications are frequently implicated in the development of human 75 
malignancies, and in these cases, are typically apparent as inappropriate gene promoter 76 
CpG island DNA methylation, histone tail modification(s), aberrant expression of micro- and 77 
long non-coding-RNAs, and less frequently, loss of gene body/intergenic methylation.17, 18 78 
These heritable modifications, or epimutations, impact upon gene expression either alone or 79 
in combination, and promote tumour evolution and/or progression by suppressing the 80 
expression of growth inhibiting and/or apoptosis promoting genes, and less frequently by 81 
leading to relaxed control of expression of growth promoting genes.17, 19, 20 82 
Epigenetic modifications and associated gene silencing have been shown in NMIBC, and 83 
specific patterns of DNA methylation, histone modifications and microRNA expression have 84 
been reported as associated with tumour growth characteristics, patient/clinical outcomes 85 
and with field defect phenomena.21, 22 However, the majority of these reports have described 86 
epigenetic changes in heterogeneous populations of NMIBC, with an abundance of low- and 87 
intermediate-grade tumours relative to high-grade tumours. With the exception of our recent 88 
candidate-gene study23 and a single report investigating the Myopodin A gene24, HG-89 
NMIBCs have not been considered as a discrete entity for the investigation of epigenetic 90 
modifications. 91 
In this study, we interrogated DNA methylation on a genome-wide scale using methylation 92 
BeadChip-array technology, in a unique cohort of HG-NMIBCs. Through comparisons with 93 
methylation levels and gene-expression in low/intermediate-grade tumours, we extend the 94 
current understanding of bladder cancer tumourigenesis and identify potential epigenetic 95 
mechanisms implicated in the development of high-grade NMIBC, and those that might 96 
represent novel therapeutic drug-targets. 97 
  98 
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Results 99 
Technical Validation of array by Pyrosequencing: 100 
Subsequent to array processing, normalisation and peak-based correction (see patients and 101 
methods), a technical validation was performed by comparing array-derived β-values with 102 
Pyrosequencing-derived methylation values. Across 120 data-points (5 CpGs, 24 samples) 103 
encompassing a broad range of array β-values, a strong positive correlation was found 104 
between the methylation values (Spearman’s rank correlation r=0.912, p<0.00001; 105 
Supplemental Figure S1). 106 
 107 
In-house filtering criteria: 108 
CpGs showing differential methylation in HG-NMIBC relative to normal bladder controls were 109 
identified following a series of stringent filtering criteria, as described previously and shown 110 
in Figure 1.25, 26 On the basis of these criteria, a total of 1,057 CpGs, representing 256 111 
genes, were identified as hypermethylated (≥0.4 β-value increase) in 15 or more of the 21 112 
high-grade tumours, relative to their mean values in the normal bladder controls. 113 
 114 
Hierarchical clustering analyses: 115 
The filtered dataset was next subject to unsupervised hierarchical cluster analysis (Figure 116 
2): the high-grade tumours cluster independently from the normal bladder control samples. 117 
In these cases, methylation is barely detectable within the normal bladder samples, whereas 118 
15 or more of the high-grade tumours show inappropriate methylation across all 1,057 CpG 119 
dinucleotides, spanning 256 gene-promoter-associated CpG islands (Supplemental Table 120 
S2).  121 
 122 
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Independent validation by Pyrosequencing: 123 
We next selected 25 genes for independent validation by Pyrosequencing on the basis of 124 
their frequent methylation in the discovery cohort that comprised 21 high-grade tumours. 125 
These analyses revealed similar frequencies and mean levels of methylation as those 126 
apparent from the BeadChip array for 24 of the 25 genes. As further confirmation, we 127 
extended the Pyrosequence analyses to an independent investigation cohort of 30 HG-128 
NMIBC tumours. Similar frequencies and mean levels of methylation between the discovery 129 
and investigation cohorts reinforced our confidence in the array-derived data (Supplemental 130 
Table S3). At this stage, and to assess for potential confounders, we assessed associations 131 
between patient demographic data and methylation patterns across these 25 genes, using 132 
separate multivariate models. No correlations were identified in these analyses, suggesting 133 
demographic factors did not significantly impact upon the methylation patterns identified 134 
(data not shown). 135 
 136 
Differential subtype-specific promoter methylation in NMIBC: 137 
We next determined methylation across the 25 genes described above in HG-NMIBC 138 
relative to that apparent in low-intermediate-grade tumours and in comparison to normal 139 
bladder controls (Supplemental Table S4). Similar to other groups27 28, we displayed these 140 
methylation data, across the high-grade and low-intermediate-grade tumours and normal 141 
controls, by heatmap (Figure 3). This demonstrated heterogeneous patterns of methylation 142 
across the 51 high- and 18 low-intermediate-grade tumours relative to the normal bladder 143 
controls. Gene-specific differences in methylation were apparent between the high-grade 144 
tumours and their low-intermediate-grade counterparts on visual inspection. Closer 145 
examination of these data showed that the differences appeared to impact on either the 146 
relative frequency and/or the mean levels of methylation between these tumour subtypes. As 147 
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examples of these differences, the ten most differentially methylated genes are shown in 148 
Table 1.  149 
 150 
Methylation frequencies in high- and low-intermediate-grade tumours: 151 
For ten of the genes we took forward for further analyses (ATP5G2, HIST1H4F, INSRR, 152 
IRF8, IRX1, PRDM14, PRRX1, TFAP2b, VAX2 and VSX1), there was an higher frequency of 153 
methylation in high-grade tumours versus low-intermediate grade tumours (Table 1). 154 
Moreover, the increases were statistically significant for the ATP5G2, VAX2 and IRX1 genes 155 
(p<0.05), and approached significance for the INSRR, IRF8, PRDM14 and VSX1 genes.  156 
 157 
Mean levels of methylation in high- and low-intermediate-grade tumours: 158 
The mean levels of methylation in the high-grade tumours were next assessed by 159 
Pyrosequencing (right-sided panel of Table 1, and Figure 4); for eight of the ten genes, 160 
mean levels of methylation were significantly greater in high-grade tumours relative to their 161 
low-intermediate-grade counterparts. In addition, and as low-intermediate-grade tumours 162 
were not subject to array analyses relative to normal bladder, further pairwise-testing was 163 
performed. This analysis identified significant differences between mean levels of 164 
methylation in the low-intermediate-grade tumours and normal bladder in four of the ten 165 
genes assessed. The range, distribution and mean levels of methylation are shown in 166 
Figure 4, and show for each of the genes, a stepwise trend toward increasing methylation 167 
from normal bladder to low-intermediate and high-grade tumours. 168 
 169 
Methylation-Associated Changes in Gene Expression: 170 
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Across the high-grade NMIBC tumours, sufficient sample was available for gene expression 171 
analyses for 17 of the 25 genes. With the exception of the ARHGEF4 gene, promoter-172 
associated CpG island methylation was negatively correlated with transcript expression for 173 
all genes assessed (data not shown). Furthermore, the presence of promoter methylation 174 
was significantly correlated with reduced transcript expression for the PON3, STAT5a and 175 
VAX2 genes (Spearman’s correlation coefficients -0.60, -0.50 and -0.48 respectively, all 176 
p<0.05). Conversely, promoter methylation was significantly positively correlated with gene 177 
transcript expression for the ARHGEF4 gene (Spearman’s correlation coefficient 0.62, 178 
p<0.05). Figure 5 shows the expression levels for these four genes across the high-grade 179 
tumours. 180 
 181 
Gene Ontology analysis of inappropriately methylated genes: 182 
Gene Ontology analyses of the 256 differentially methylated genes identified ‘over-183 
representation’ of multiple categories of biological processes, molecular functions and 184 
pathways. In particular, highly significant over-representation was identified for specific 185 
biological processes, including regulation of RNA polymerase II activity and DNA 186 
transcription, and for pathways involving cell adhesion and PI3K-Akt signalling 187 
(Supplemental Table S5). 188 
  189 
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Discussion 190 
In common with most other tumour types, bladder cancers harbour epigenetic aberrations 191 
which are frequently apparent as inappropriate DNA methylation.8, 22, 29 However, reports are 192 
limited and largely confined to heterogeneous patient cohorts of NMIBC or MIBC;30 despite 193 
their clinical importance, high-grade NMIBC tumours are rarely investigated as a discrete 194 
entity in the context of disease and/or subtype-specific epigenetic modifications.23 To 195 
address this, we performed genome-wide analyses of DNA methylation using BeadChip 196 
array technology in high-grade NMIBC, comprising a discrete cohort of tumours recruited at 197 
initial presentation. This analysis, the first ‘450K array’ interrogation in bladder cancer, 198 
revealed multiple and novel frequently differentially methylated genes in these tumours 199 
relative to normal bladder. Through Pyrosequence analysis of sodium bisulphite converted 200 
DNA, we extended our analyses to include independent cohorts of high- and low-201 
intermediate-grade tumours. These investigations confirmed the array-derived data for the 202 
high-grade tumours, and showed them as harbouring significantly increased frequencies 203 
and/or mean levels of gene-specific methylation relative to low-intermediate-grade tumours. 204 
Moreover, for some of the genes investigated, a significant inverse correlation between 205 
promoter methylation and gene expression levels was apparent and suggests their potential 206 
as targets for therapeutic intervention.29 31 32 207 
 208 
Initially we performed a technical validation of the discovery cohort data by Pyrosequence 209 
analysis of converted DNA.25 33 34 In common with previous reports and across multiple 210 
genes, these analyses confirmed and reinforced the array-derived data.34 35 36 These 211 
analyses also showed that for the majority of regions investigated, methylation extended to 212 
include contiguous promoter-associated CpG sites. On the basis of  previous reports from 213 
our own and other groups,37 38 we employed stringent criteria (β-value differences ≥0.4) to 214 
identify differentially methylated genes across multiple CpG sites; such criteria are more 215 
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consistently associated with bona fide changes in methylation, and are more likely to show 216 
associations with gene expression.37, 39 40, 41 217 
The analysis of the discovery cohort of high-grade NMIBC identified 1,057 CpGs, across 256 218 
gene-promoter-associated CpG islands. Cluster analysis and heat map display of these 219 
regions revealed extensive and frequent differential methylation in the tumours relative to 220 
normal bladder controls. As our study represents the first 450K analysis of high-grade 221 
bladder cancer a direct ‘like-for-like’ comparisons of our findings with those of other groups 222 
was not possible; however, the number of differentially methylated sites we identified 223 
appeared to be lower than those previously reported in other tumour types.42 43 Potential 224 
explanations for these findings are the tumour type per se and/or the stringency of our 225 
inclusion-exclusion criteria and definition of differential methylation.44  226 
For the genes identified, we performed gene ontology and KEGG pathway analyses. In 227 
these cases we identified significant over-representation of genes in processes and 228 
pathways previously reported by other groups as subject to epigenetically-mediated 229 
dysregulation in tumour development. For examples, these included transcription and cell 230 
signalling and adhesion45-47, suggesting possible similar roles in high-grade bladder tumours, 231 
and their validity as targets for further investigation. 232 
We next extended our investigation of multiple novel genes to an independent cohort of 233 
high-grade tumours, and a cohort of low-intermediate-grade tumours for comparison. Similar 234 
frequencies and mean levels of methylation, as determined by Pyrosequence analysis, were 235 
apparent within the discovery and investigation cohorts of high-grade tumours, suggesting 236 
our approach for the identification of candidates by array analysis was robust. Interestingly, 237 
many of the genes identified as novel and differentially methylated were also inappropriately 238 
methylated in low-intermediate-grade tumours. However, and despite the absence of genes 239 
as being exclusively associated with either high- or low-intermediate-grade tumours, the 240 
frequency and mean levels of gene-promoter methylation in the high-grade tumours were 241 
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significantly higher than in the low-intermediate-grade tumours. Indeed, similar observations 242 
with respect to differences in the frequencies of methylation between high- and low-grade 243 
bladder tumours were first suggested by Ibragimova et al.47 Similar subtype and/or grade-244 
associated differences have been reported in other tumour types including, pituitary, breast, 245 
and colon cancer subtypes.37, 48, 49 In our analysis of NMIBC it remains unclear whether the 246 
increase in frequency and/or mean levels of methylation in the more aggressive tumours 247 
represents a more rapid accumulation of epigenetic changes during tumour progression, or 248 
reflects distinct epigenetic pathways of tumour development and outgrowth.50, 51 Our findings 249 
may therefore reflect either of the described scenarios in the more aggressive (high-grade) 250 
tumours and suggests that these tumours are either consequent to progression from low-251 
intermediate-grade tumours, or are the progeny of aberrations in distinct epigenetic 252 
pathways within these NMIBC subtypes. Moreover, the identification of different patterns of 253 
methylation between tumours represents an important area for future investigation. In this 254 
case, methylation may hold promise as an ‘at diagnosis’ biomarker of long-term tumour 255 
outcome, similar to that described in colorectal, breast and lung cancers. 52-54 256 
Although many of the novel genes we identified have not been previously reported in 257 
bladder cancer, their inappropriate methylation, accompanied with gene-silencing, has been 258 
reported in the context of other tumour types and suggests potential roles as tumour 259 
suppressor genes.55, 56 57 To determine associations between methylation and gene 260 
expression, we confined our studies to genes showing frequent and/or high mean levels of 261 
methylation. For the majority of gene-transcripts we investigated, promoter methylation was 262 
negatively correlated with reduced transcript expression, although not significantly so (data 263 
not shown). However, as described by our own and other groups, this may reflect a 264 
passenger-driver phenomenon where, in the ‘passenger’ context, gene expression is not 265 
directly influenced by the observed epigenetic modification(s).58 59 However, for four of 266 
seventeen transcripts we examined, significant correlations between methylation and 267 
transcript expression were apparent. In these cases, and for the PON3, STAT5a and VAX2 268 
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genes, promoter methylation was significantly associated with reduced gene expression, 269 
whilst the converse was true for the ARHGEF4 gene. Such associations are similar to those 270 
described previously in multiple other cancers and in NMIBC. 20, 21 43  Indeed, for two of these 271 
genes, PON3 and STAT5a, previous studies in mice and cell-line models have described 272 
potential tumour suppressor roles.60 61 If this is the case, then these genes may represent 273 
important targets for further studies of functional the significance of methylation and reduced 274 
expression in a bladder tumour context, including in-vitro investigations of de-methylating 275 
agents designed to restore gene expression. 276 
In summary, we have presented the first comprehensive genome-wide DNA methylation 277 
analysis of NMIBC in a unique cohort of high-grade tumours. The study has reported an 278 
increase in the frequency and/or mean levels of methylation at gene promoter-associated 279 
CpG islands in high-grade tumours relative to their low-intermediate-grade tumour 280 
counterparts, that in some cases is associated with reduced gene expression. These 281 
findings suggest that epigenetic modifications, alone or in combination with other 282 
aberrations, are causal in the development and/or progression of this tumour type. Further 283 
studies are required to assess the functional significance of epigenetic changes in HG-284 
NMIBC; however, we suggest that the genes identified hold significant potential as targets 285 
for novel therapeutic interventions alone, or in combination, with conventional therapeutic 286 
options in the treatment of this clinically unpredictable disease. 287 
 288 
 289 
  290 
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Patients and methods 291 
Human tissue samples 292 
Primary tumour and normal bladder tissues used were provided by the Bladder Cancer 293 
Prognosis Programme (BCPP, National Research Ethics Service East Midlands - Derby 294 
06/MRE04/65.)62, the University of Birmingham Human Biomaterials Resource Centre 295 
(National Research Ethics Service (North West 5): 09/H1010/75), and the University 296 
Hospitals of North Midlands NHS Trust (National Research Ethics Service (South Central – 297 
Oxford C): 12/SC/0725). All samples were confirmed histologically as normal bladder 298 
urothelium (control, n=4), G3pT1 TCC (high-grade: discovery cohort n=21, investigation 299 
cohort n=30), and G1/2 pTa/1 TCC (low/intermediate-grade: n=18). As previously 300 
described23, patients received repeat bladder tumour resection (TURBT), cystectomy and/or 301 
intra-vesical therapy as recommended by European Association of Urology guidelines.63 All 302 
samples (details are provided in Supplemental Table S1) were stored at -80oC prior to 303 
nucleic acid extraction, as described below. 304 
 305 
DNA extraction and bisulphite modification 306 
Genomic DNA was extracted from tumour and control tissues using a standard phenol-307 
chloroform procedure 64, then bisulphite-converted using the EZ DNA Methylation Gold kit 308 
(Zymo Research) as we have previously described.37 Bisulphite-conversion of DNA was 309 
confirmed in all cases by successful PCR using primers specific to bisulphite-converted DNA 310 
(primer sequences in Supplemental Table S6). To increase the relative amount and stability 311 
of bisulphite-converted DNA, whole-genome amplification (WGA) was performed as 312 
previously described.37 313 
 314 
 315 
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Illumina 450K Methylation Bead-Array Analyses 316 
Bisulphite-converted DNA from 21 bladder tumours and three normal controls was 317 
hybridised to Infinium-based HumanMethylation450 BeadChip arrays (Illumina, San Diego, 318 
CA, USA) to quantify DNA methylation at approximately 480,000 CpG positions across the 319 
genome, representing more than 21,000 RefSeq genes. In this case, normal bladder was 320 
used as control for consistency with previous array analyses 35, 47, 65, and also to permit 321 
comparisons with earlier reports of non-muscle invasive bladder cancer. Arrays were 322 
processed according to the manufacturer’s instructions (performed by Barts and the London 323 
Genome Centre, UK), as described by us previously.66  324 
Raw array data were processed using GenomeStudio software and the bioinformatical 325 
platform ‘NIMBL’, as we 67, 68 and others69 have described. For each probe, the methylation 326 
status was reported as a methylation ‘β-value’, where ‘β’ is defined as the ratio of the 327 
methylated signal intensity over the summed intensity of the methylated and unmethylated 328 
signals + 100.40 β-values range from 0 (unmethylated) to 1 (fully methylated). NIMBL was 329 
used to perform ‘peak-based’ correction, to adjust for potential differences in array probe-330 
type sensitivity previously reported33; all comparative analyses of high-grade tumours to 331 
normal bladder controls, were performed on peak-based corrected β-values, as described by 332 
us previously.68  333 
Each array passed quality control assessment based upon the performance of internal 334 
controls and the distribution of β-values across all array CpGs. As previously described68, 335 
and represented by step 1 of Figure 1, we excluded all CpGs for which any of the 24 336 
samples displayed: (i) probe detection p-values >0.05 (unreliable probe data), or (ii) missing 337 
β-values (preventing analyses of all samples). We also excluded all CpG loci on allosomes 338 
(reducing confounding gender-based methylation differences). We used a series of stringent 339 
filtering criteria, shown in Figure 1 and described in the Results section, to identify 340 
15 
 
inappropriate methylation, defined as a β-value difference ≥0.4, in tumour samples relative 341 
to the mean of the normal bladder controls. 342 
 343 
Unsupervised hierarchical clustering using average linkage criteria was performed using 344 
Genesis software (v1.7.6).70 Gene Ontology (GO) analyses were performed using 345 
http://geneontology.org/ and http://gather.genome.duke.edu/, and Kyoto Encyclopaedia of 346 
Genes and Genomes (KEGG) analyses with http://www.genome.jp/kegg/ online platforms, 347 
respectively. Bonferroni correction71 was employed in all GO and KEGG pathway analyses. 348 
 349 
Technical validation of Methylation Bead-Chip Array Data 350 
Five CpG loci encompassing a broad range of β-values derived from 450k array analyses, 351 
were assessed by Pyrosequencing (described below), using identical samples, to 352 
independently validate the array data (β-values vs. methylation %). Correlation between the 353 
methods was assessed across a total of 120 CpGs using Spearman’s rank correlation, as 354 
shown in Supplemental Figure S1. Primer sequences are provided in Supplemental Table 355 
S6. 356 
 357 
Pyrosequencing™ of sodium bisulphite-converted DNA 358 
Validation of array data (discovery cohort) and further quantitative assessment of 359 
methylation in the independent (investigation) tumour cohort were performed by 360 
Pyrosequencing of sodium bisulfite-converted DNA, as previously described by us66, using a 361 
PyroMark Q24 Pyrosequencer, PyroMark Q24 Software 2.0 and PyroMark Gold Q24 362 
Reagents. Dependent on the specific gene, and the density of CpGs within their promoter-363 
associated CpG island, between five and nine consecutive CpG sites were assessed. 364 
Promoter methylation was defined in tumours if the mean level of methylation across the 365 
assessed CpG island was greater either than four standard deviations (4SD), or 20% above, 366 
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the mean of the normal controls.37 The number of tumours methylated for any given gene 367 
describes the frequency of methylation, whereas the mean percentage methylation per se of 368 
all of the CpGs surveyed within a gene describes the mean level of methylation. 369 
 370 
Quantitative RT-PCR 371 
Total RNA was extracted from control and tumour samples using a standard guanidinium 372 
thiocyanate-phenol-chloroform protocol 72. Complementary DNA (cDNA) was synthesised as 373 
described previously73. Thermal cycling using SYBR Green was as previously described74, 374 
with target genes normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 375 
the endogenous control gene (Supplemental Table S6). Relative quantification of transcript 376 
expression was performed using the 2-∆∆ cycle threshold (CT) method75, and as previously 377 
described76. Reduced transcript expression in a tumour was defined where expression was 378 
at least 3-fold lower than the mean level of expression observed in control samples; the 379 
converse was true for increased transcript expression.37 38 77 380 
 381 
Non-Array Informatics and statistics. 382 
STATA (version 8, Stata Corporation, College Station, TX) was used to analyse methylation 383 
and gene expression data in tumour and normal cohorts using Fisher’s exact tests 384 
(frequency of methylation), Student’s t-tests (mean level of methylation), and Spearman 385 
correlation coefficients (associations between methylation and gene expression). p-values 386 
<0.05 were considered statistically significant. 387 
  388 
17 
 
Ethics Committee Approvals 389 
East Midlands - Derby: 06/MRE04/65. 390 
The University of Birmingham Human Biomaterials Resource Centre (National Research 391 
Ethics Service (North West 5): 09/H1010/75. 392 
The University Hospitals of North Midlands NHS Trust (National Research Ethics Service 393 
(South Central – Oxford C): 12/SC/0725. 394 
  395 
18 
 
Reagents 396 
EZ DNA Methylation Gold kit, Zymo Research, D5005 397 
HumanMethylation450 BeadChip arrays, Illumina, WG-314-1003 398 
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Figure Legends 636 
 637 
Figure 1. Array filtering steps. Summary of the steps implemented for the identification of 638 
CpGs hypermethylated in HG-NMIBC. The initial filtering steps (*) included exclusion of non-639 
significant probe data, probes with missing data and probes located on allsomes.  640 
RefSeq (National Center for Biotechnology Information Reference Sequence Database). 641 
CpG island based upon the UCSC genome browser definition from Gardiner-Garden and Frommer78.  642 
 643 
Figure 2. Unsupervised hierarchical clustering analysis of the 1,057 gene promter-644 
associated hypermethylated CpGs in HG-NMIBC. Heatmap and dendrogram of 645 
differentially methylated gene promoter-associated CpG sites identified by array analysis. 646 
The dendrogram above the heatmap separates normal bladder (green bar, n=3) and high-647 
grade-NMIBC bladder tumours (red bar, n=21). Each row represents an individual CpG 648 
locus, and each column represents a normal control or tumour sample (listed beneath the 649 
heatmap). The colour scale beneath the heatmap represents methylation status: 650 
unmethylated is yellow (β-value=0.0), and fully methylated is blue (β-value=1.0). 651 
 652 
Figure 3. Heatmap for 25 hypermethylated gene promoter-associated CpG islands. 653 
Pyrosequencing validation of 25 gene promoter-associated CpG islands, identified as 654 
frequently differentially methylated in high-grade tumours by 450k BeadChip-array analysis. 655 
As indicated above the heatmap, the four normal bladder controls are presented to the left-656 
side of the heatmap, followed by 18 low-intermediate-grade tumours, and 51 high-grade 657 
tumours (the combined discovery and investigation cohorts). Each row represents the 658 
promoter-associated CpG island of the indicated gene, and each colour block the mean level 659 
of methylation across the island. The colour scale beneath the heatmap represents 660 
methylation status: unmethylated is green (0.0% methylation), and fully methylated is red 661 
(100.0% methylated). 662 
26 
 
Figure 4. Mean levels of methylation in high-grade tumours relative to low-663 
intermediate-grade tumours and normal bladder. Top ten genes showing an increase in 664 
mean level of methylation (solid red bar) in high-grade tumours (HG, n=51) relative to low-665 
intermediate-grade tumours (LG, n=18) and in comparison to normal bladder controls (C, 666 
n=4). Each individual control or tumour sample is shown as an unfilled blue circle. Significant 667 
differences in the mean levels of methylation between the low-intermediate- and high-grade 668 
tumours, or between control and low-intermediate-grade tumours, are indicated by *, p<0.05, 669 
or **, p<0.005 (Student’s T-test). 670 
 671 
Figure 5. Association of methylation with gene transcript expression in HG-NMIBC. 672 
Tumour transcript expression in unmethylated (UM, unfilled circles) and methylated (M, filled 673 
circles) high-grade tumours, relative to normal bladder control (C, unfilled triangles) for the 674 
four genes showing significant Spearman’s correlation coefficients between promoter 675 
methylation and gene expression (PON3, STAT5a, VAX2 and ARHGEF4; p=0.0006, 676 
p=0.005, p=0.013 and p=0.0007, respectively). The double-headed arrow represents the 677 
threshold for 3-fold reduced expression relative to the mean of the normal controls (solid 678 
blue bar); expression at or below this threshold signifies reduced expression in tumour 679 
samples.  680 
 681 
 682 
  683 
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Tables 684 
 685 
 
METHYLATION 
 FREQUENCY  
MEAN LEVEL OF 
METHYLATION  
Gene 
Symbol 
High-grade Low-intermediate-
grade 
 High-grade Low-intermediate-
grade 
 
 Number   (%) Number   (%) P value (%) (%) P value 
ATP5G2 37/51  (72.5) 6/18  (33.3) 0.005 51.04 30.20 0.029 
VAX2 13/51  (25.5) 0/18  (0.0) 0.015 32.31 19.56 0.004 
IRX1 37/51  (72.5) 8/18  (44.4) 0.045 49.47 38.70 0.067 
INSRR 29/51  (56.9) 5/18  (27.8) 0.054 24.06 24.06 0.028 
IRF8 25/51  (49.0) 4/18  (22.2) 0.057 26.13 17.99 0.157 
PRDM14 45/51  (88.2) 12/18  (66.7) 0.066 60.14 46.06 0.029 
VSX1 44/51  (86.3) 12/18  (66.7) 0.086 56.37 38.26 0.0004 
TFAP2b 22/51  (43.1) 4/18  (22.2) 0.160 32.25 17.68 0.047 
PRRX1 27/51  (52.9) 7/18  (38.9) 0.413 47.03 34.36 0.041 
HIST1H4F 42/51  (82.4) 13/18  (72.2) 0.496 59.46 41.91 0.017 
 686 
Table 1. Genes showing the greatest methylation increase in high-grade relative to 687 
low-intermediate-grade NMIBC tumours. Top ten genes showing an increase in frequency 688 
of methylation (left side of table), and/or an increase in mean level of methylation (right side 689 
of table) in high-grade tumours relative to low-intermediate-grade tumours. For the left side 690 
of the table, the number and proportion of tumours methylated are displayed for the low-691 
intermediate- and high-grade cohorts, with p-value (Fishers exact, p<0.05 significant). For 692 
the right side of the table, the mean level of methylation across the low-intermediate- and 693 
high-grade tumour cohorts are displayed with p-value (Student’s T-Test, p<0.05 significant). 694 
Statistically significant p-values are displayed in bold. 695 
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Supplemental Data 696 
 697 
Figure S1. Technical validation of 450k BeadChip-array data. Correlation between array-698 
derived β-values (x-axis) and methylation percentage as determined by Pyrosequencing (y-699 
axis) for 5 CpGs (cg07778029, cg14456683, cg01227537, cg05661282 and cg26465391) 700 
across 24 samples is shown. Spearman-rank correlation coefficient r=0.912; p<0.00001. 701 
 702 
Table S1. Sample characteristics. 703 
 704 
Table S2. List of 256 differentially methylated genes. 705 
 706 
Table S3. Methylation in discovery and investigation high-grade tumour cohorts. 707 
 708 
Table S4. Frequency and mean levels of methylation in 25 genes for high- and low-709 
intermediate-grade tumours. 710 
 711 
Table S5. Gene Ontology and KEGG pathway annotation lists. 712 
 713 
Table S6. Primer sequences. 714 
 715 
 716 
 717 
